CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Artemisinin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00753506
NCT00753506N/ACompleted
CompareCT.gov

Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia

Sheppard Pratt Health System·interventional·Posted Sep 16, 2008·Updated Feb 28, 2012

In Brief

A clinical study evaluating Artemisinin and Identical looking placebo capsule for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the antimalarial compound artemisinin when used in addition to standard antipsychotic medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2008
Enrollment StartAug 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.8 years ago

Interventions

Artemisinindietary

100 mg of artemisinin twice per day for 10 weeks

Identical looking placebo capsuledietary

Identical looking placebo twice per day for 10 weeks